Stay updated on PF-06650833/PF-06700841/PF-06826647 in Hidradenitis Suppurativa Clinical Trial
Sign up to get notified when there's something new on the PF-06650833/PF-06700841/PF-06826647 in Hidradenitis Suppurativa Clinical Trial page.

Latest updates to the PF-06650833/PF-06700841/PF-06826647 in Hidradenitis Suppurativa Clinical Trial page
- Check2 days agoChange DetectedThe ClinicalTrials.gov page footer now displays revision v3.8.1 instead of v3.8.0.SummaryDifference0.0%

- Check9 days agoChange DetectedThe record describes a completed Phase 2 study of three Pfizer kinase inhibitors for adults with moderate-to-severe hidradenitis suppurativa, including its eligibility criteria, participating locations, and outcome measures. It also provides study documents and information about requesting access to de-identified participant data.SummaryDifference92%

- Check16 days agoChange DetectedThe footer’s site revision changed from v3.7.2 to v3.8.0; the page still displays a 403 Forbidden error.SummaryDifference0.2%

- Check30 days agoChange DetectedA sitewide NIH notice about a terminology transition from “Artificial Intelligence” to “Super Intelligence” appears above the 403 error page. The site revision label also changes from v3.7.1 to v3.7.2.SummaryDifference1%

- Check44 days agoChange DetectedThe footer revision label changes from v3.7.0 to v3.7.1 while the page continues to display a 403 Forbidden error.SummaryDifference0.2%

- Check58 days agoChange DetectedThe page now displays a 403 Forbidden error instead of the study record content, preventing access to the study details.SummaryDifference19%

Stay in the know with updates to PF-06650833/PF-06700841/PF-06826647 in Hidradenitis Suppurativa Clinical Trial
Enter your email address, and we'll notify you when there's something new on the PF-06650833/PF-06700841/PF-06826647 in Hidradenitis Suppurativa Clinical Trial page.